126 related articles for article (PubMed ID: 11342370)
21. Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis.
Villamizar O; Chambers CB; Riberdy JM; Persons DA; Wilber A
Oncotarget; 2016 Mar; 7(12):13810-26. PubMed ID: 26885613
[TBL] [Abstract][Full Text] [Related]
22. Aberrant processing of Fas transcripts in adult T-cell leukemia: a possible role in tumor cell survival.
Tawara M; Maeda T; Yamada Y; Harasawa H; Tsuruda K; Sugahara K; Moriuchi R; Tomonaga M; Kamihira S
Cancer Lett; 2003 Apr; 193(2):235-42. PubMed ID: 12706882
[TBL] [Abstract][Full Text] [Related]
23. CD95 (APO-1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants.
Wood CM; Goodman PA; Vassilev AO; Uckun FM
Eur J Haematol; 2003 Mar; 70(3):156-71. PubMed ID: 12605660
[TBL] [Abstract][Full Text] [Related]
24. Membrane and soluble forms of Fas (CD95) in peripheral blood lymphocytes and in serum from burns patients.
Lebedev MJ; Ptitsina JS; Vilkov SA; Korablev SB; Novikov VV
Burns; 2001 Nov; 27(7):669-73. PubMed ID: 11600245
[TBL] [Abstract][Full Text] [Related]
25. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias.
Kamihira S; Yamada Y; Hirakata Y; Tsuruda K; Sugahara K; Tomonaga M; Maeda T; Tsukasaki K; Atogami S; Kobayashi N
Br J Haematol; 1997 Dec; 99(4):858-65. PubMed ID: 9432034
[TBL] [Abstract][Full Text] [Related]
26. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.
Robertson MJ; Manley TJ; Pichert G; Cameron C; Cochran KJ; Levine H; Ritz J
Leuk Lymphoma; 1995 Mar; 17(1-2):51-61. PubMed ID: 7539660
[TBL] [Abstract][Full Text] [Related]
27. Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95).
Stanger BZ
Mol Med; 1996 Jan; 2(1):7-20. PubMed ID: 8900530
[TBL] [Abstract][Full Text] [Related]
28. Possible attenuation of fas-mediated signaling by dominant expression of caspase-8 aberrant isoform in adult T-cell leukemia cells.
Sugahara K; Hayashi T; Dateki N; Hirakata Y; Harasawa H; Tomonaga M; Yamada Y; Kamihira S
Int J Hematol; 2002 Jul; 76(1):50-4. PubMed ID: 12138895
[TBL] [Abstract][Full Text] [Related]
29. Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms.
Tsuruda K; Yamada Y; Hirakata Y; Sugahara K; Maeda T; Atogami S; Tomonaga M; Kamihira S
Leuk Res; 1999 Feb; 23(2):159-66. PubMed ID: 10071131
[TBL] [Abstract][Full Text] [Related]
30. Soluble Fas mRNA is dominantly expressed in cases with silicosis.
Otsuki T; Sakaguchi H; Tomokuni A; Aikoh T; Matsuki T; Kawakami Y; Kusaka M; Ueki H; Kita S; Ueki A
Immunology; 1998 Jun; 94(2):258-62. PubMed ID: 9741350
[TBL] [Abstract][Full Text] [Related]
31. Modulation of fas-mediated apoptosis in osteosarcoma cell lines.
Hamada T; Komiya S; Yano H; Zenmyo M; Hiraoka K; Inoue A; Morimatsu M
Int J Oncol; 1999 Dec; 15(6):1125-31. PubMed ID: 10568818
[TBL] [Abstract][Full Text] [Related]
32. A naturally occurring soluble isoform of murine Fas generated by alternative splicing.
Hughes DP; Crispe IN
J Exp Med; 1995 Nov; 182(5):1395-401. PubMed ID: 7595210
[TBL] [Abstract][Full Text] [Related]
33. Human hepatocytes produce an isoform of FAS that inhibits apoptosis.
Krams SM; Fox CK; Beatty PR; Cao S; Villanueva JC; Esquivel CO; Martinez OM
Transplantation; 1998 Mar; 65(5):713-21. PubMed ID: 9521208
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia alters splicing of the cancer associated Fas gene.
Peciuliene I; Vilys L; Jakubauskiene E; Zaliauskiene L; Kanopka A
Exp Cell Res; 2019 Jul; 380(1):29-35. PubMed ID: 31002816
[TBL] [Abstract][Full Text] [Related]
35. Balanced regulation of mRNA production for Fas and Fas ligand in lymphocytes from centenarians: how the immune system starts its second century.
Pinti M; Troiano L; Nasi M; Bellodi C; Ferraresi R; Mussi C; Salvioli G; Cossarizza A
Circulation; 2004 Nov; 110(19):3108-14. PubMed ID: 15505087
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils.
Luttmann W; Opfer A; Dauer E; Foerster M; Matthys H; Eibel H; Schulze-Osthoff K; Kroegel C; Virchow JC
Eur J Immunol; 1998 Jul; 28(7):2057-65. PubMed ID: 9692873
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
38. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
Komada Y; Sakurai M
Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
[TBL] [Abstract][Full Text] [Related]
39. The conformational alteration of the mutated extracellular domain of Fas in an adult T cell leukemia cell line.
Maeda T; Nakayama S; Yamada Y; Sugahara K; Isomoto H; Tawara M; Yamasaki R; Onimaru Y; Matsushita T; Ohzono Y; Kamihira S
Biochem Biophys Res Commun; 2002 Sep; 296(5):1251-6. PubMed ID: 12207908
[TBL] [Abstract][Full Text] [Related]
40. Fas antigen/APO-1 (CD95) expression on myeloma cells.
Shima Y; Nishimoto N; Yoshizaki K; Kishimoto T
Leuk Lymphoma; 1996 Nov; 23(5-6):521-31. PubMed ID: 9031082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
